LSDIF (Lucy Scientific Discovery) EBIT: $-8.53 Mil (TTM As of Dec. 2023)

What is Lucy Scientific Discovery EBIT?

Lucy Scientific Discovery LSDIF EBIT is $-8.53 Mil as of Dec. 2023.

Lucy Scientific Discovery's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.18 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.53 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lucy Scientific Discovery's annualized ROC % for the quarter that ended in Dec. 2023 was -72.53%. Lucy Scientific Discovery's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -571.78%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Lucy Scientific Discovery (OTCPK:LSDIF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lucy Scientific Discovery's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-3.452 * ( 1 - 0% )	/	( (5.076	+	4.443)	/ 2 )
=	-3.452	/	4.7595
=	-72.53 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.266	-	1.827	-	( 0.238	-	max(0, 2.226	-	1.589	+	0.238	))
=	5.076

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.287	-	1.993	-	( 0.211	-	max(0, 3.487	-	1.338	+	0.211	))
=	4.443

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Lucy Scientific Discovery's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.7	/	( ( (1.644 + max(-0.486, 0))	+	(0 + max(-0.874, 0)) )	/	2 )
=	-4.7	/	( ( 1.644	+	0 )	/	2 )
=	-4.7	/	0.822
=	-571.78 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.341)	-	(1.827	+	0	+	0)
=	-0.486

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.001	+	0	+	1.118)	-	(1.993	+	0	+	0)
=	-0.874

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lucy Scientific Discovery's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-8.527	/	0.000
	=	%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucy Scientific Discovery EBIT Related Terms

Lucy Scientific Discovery EBIT Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's EBIT can be seen below:

Lucy Scientific Discovery EBIT Chart

Lucy Scientific Discovery Annual Data

Trend

Jun21

Jun22

Jun23

EBIT

-2.37

-3.79

-7.02

Lucy Scientific Discovery Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial						-0.18	-3.57	-2.18	-1.61	-1.18

LSDIF vs INQD, ZTS, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucy Scientific Discovery EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's EV-to-EBIT falls into.

Save Embed

Lucy Scientific Discovery EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.53 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-8.53 Mil mean?

Lucy Scientific Discovery (LSDIF) has a EBIT of $-8.53 Mil as of Dec. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lucy Scientific Discovery.

Is Lucy Scientific Discovery's EBIT too high?

Lucy Scientific Discovery's current EBIT is $-8.53 Mil.

How does Lucy Scientific Discovery's EBIT compare to INQD and ZTS?

Lucy Scientific Discovery's EBIT of $-8.53 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lucy Scientific Discovery. Lucy Scientific Discovery's current EBIT is $-8.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lucy Scientific Discovery stock overvalued right now?

Lucy Scientific Discovery (LSDIF) has a current EBIT of $-8.53 Mil. The current EBIT is $-8.53 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current EBIT is $-8.53 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies INQD ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS SZSE:000538 HKSE:03692 NBIX NSE:TORNTPHARM BOM:543904 BOM:500124 TSE:4507 CTLT BOM:532321

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6

Website https://www.lucyscientific.com

Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.